Very good, statistically significant improvement in BCVA, and...

Very good, statistically significant improvement in BCVA, and they’ve been able to structure the phase 3 trial in such a way that takes the types of patients who responded best in P2 and focuses on them (likely meaning that P3 actually outperforms P2). So not only did the P2 trial show a solid result but they’ve learned from it to improve the odds of blockbuster result in P3. The management team here have extensive experience bringing some of the most successful AMD (and other) drugs to market previously so I think we can be fairly confident that they’ve conducted this trial in such a way that maximises the outcome.

All this information can be discovered in past announcements released by the company. Highly recommend viewing some of the recent presentations, plus you should also be able to find the P2 results if you scroll far enough back